Medplus Health Services Share News - Latest Updates, Live News & More

Latest news about Medplus Health Services

MedPlus Health Services Subsidiary Faces Drug License Suspension in Maharashtra 3 hrs ago Today

MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a fifteen-day drug license suspension for a store in Sasanenagar, Pune, Maharashtra. The suspension was issued by the Assistant Commissioner & Licensing Authority, Food & Drug Administration, Maharashtra, under Rule 65 of the Drugs and Cosmetics Act, 1940. The company estimates a potential revenue loss of Rs 6.27 lacs from this regulatory action.

MedPlus Health Services Subsidiary Faces 25-Day Drug License Suspension in Maharashtra 3 days ago

MedPlus Health Services Allots 2,32,061 Equity Shares Under ESOP 2021 Scheme 4 days ago

MedPlus Health Services Reports Strong Q3FY26 Results with 15.67% Revenue Growth 5 days ago

MedPlus Health Services Subsidiary Receives Drug License Suspension for Telangana Store 5 days ago

More news about Medplus Health Services

22Jan 26

MedPlus Health Services Schedules Q3FY26 Earnings Call for February 02, 2026

MedPlus Health Services Limited has scheduled its Q3FY26 earnings call for February 02, 2026, at 4:00 PM IST to discuss unaudited financial results for the quarter ended December 31, 2025. The announcement complies with SEBI Regulation 30 requirements and provides multiple participation options including online pre-registration and international dial-in numbers covering 18 countries. The earnings call information will be available on the company website and both BSE and NSE platforms.

13Jan 26

MedPlus Health Services Subsidiary Faces Drug License Suspensions Across Multiple Stores

MedPlus Health Services subsidiary Optival Health Solutions received six drug license suspension orders from authorities in Karnataka and Telangana, affecting multiple stores with suspension periods of 1-4 days. The total potential revenue loss is estimated at ₹6.98 lakhs, with orders received between January 10-12, 2026, under the Drugs and Cosmetics Act provisions.

03Jan 26

MedPlus Health Services Reports Drug License Suspension at Subsidiary Store in Karnataka

MedPlus Health Services disclosed that its subsidiary Optival Health Solutions Private Limited received a one-day drug license suspension for its store at KC Rani Road, Gadag, Karnataka. The order was issued by the Assistant Director of Drugs Control Administration under Rule 65 of the Drugs and Cosmetics Act, 1940, with the company estimating a potential revenue loss of ₹0.23 lacs from this regulatory action.

01Jan 26

MedPlus Health Services Subsidiary Faces Drug License Suspension in Andhra Pradesh

MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a seven-day drug license suspension order for a store in Andhra Pradesh. The suspension was issued by Vijayawada's Drugs Control Administration under the Drugs and Cosmetics Act, with the company estimating a potential revenue loss of ₹2.10 lakhs from this regulatory action.

01Jan 26

Medplus Health Services Subsidiary Faces Drug License Suspension in Andhra Pradesh

Medplus Health Services has reported that its subsidiary faces a drug license suspension in Andhra Pradesh, with the company projecting a revenue loss of ₹2.10 lakhs from this regulatory action. The financial impact appears modest relative to the company's overall operations.

31Dec 25

MedPlus Health Services Subsidiary Receives Drug License Suspension Order in Telangana

MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a one-day drug license suspension order from Telangana's Drugs Control Administration for a store in Vanasthalipuram Ganesh Temple area. The regulatory action, taken under the Drugs and Cosmetics Act, resulted in an estimated revenue loss of ₹1.19 lakhs, with the order received on December 30, 2025.

29Dec 25

Medplus Health Services: Catalyst Trusteeship Releases 41.72 Lakh Pledged Equity Shares

Catalyst Trusteeship Limited released 41,71,970 pledged equity shares of Medplus Health Services on December 24, 2025. This reduced the encumbered shareholding from 9.01% to 5.53% of the total share capital. The release was executed under SEBI's Substantial Acquisition of Shares and Takeovers Regulations, 2011. Medplus Health Services' total equity share capital remains unchanged at ₹23.96 crores, consisting of 11,98,22,581 shares with a face value of ₹2.00 each.

24Dec 25

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka

Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at three retail locations in Karnataka. The suspensions, issued by the Assistant Director of Drugs Control Administration, are for three days each and affect stores in Jayanagar, T R Nagar, and Shiggon Haveri. The potential revenue loss from these suspensions is estimated at ₹3.24 lakhs. The company disclosed this information to stock exchanges in compliance with SEBI regulations.

20Dec 25

MedPlus Health Services Subsidiary Faces Drug License Suspension in Maharashtra

MedPlus Health Services' subsidiary, Optival Health Solutions, has received a 10-day drug license suspension order for a store in Ahmednagar, Maharashtra. The order was issued by the Assistant Commissioner Licensing Authority, Food Drug Administrations, Ahmednagar. The company estimates a potential revenue loss of ₹2.00 lakhs due to this suspension.

18Dec 25

MedPlus Promoters Release 41.72 Lakh Pledged Shares Following Debt Repayment

MedPlus Health Services announced the release of 41.72 lakh pledged shares by promoter Agilemed Investments Private Limited on December 24, following successful debt repayment of ₹321 crores. The release reduced the promoter group's total pledge level from 27.96% to 24.48% of share capital, demonstrating improved financial flexibility and reduced leverage at the promoter level.

14Dec 25

MedPlus Health Services Subsidiary Faces Drug License Suspensions in Maharashtra

Optival Health Solutions, a subsidiary of Medplus Health Services, has received suspension orders for drug licenses affecting three stores in Maharashtra. The suspensions, lasting five days each, impact locations in Amravati and Nagpur districts. The total potential revenue loss from these suspensions is estimated at ₹10.17 lakhs. The company has disclosed this information in compliance with SEBI regulations.

11Dec 25

MedPlus Health Services Subsidiary Faces Drug License Suspension in Karnataka

MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a five-day drug license suspension order from Karnataka's Drug Control Administration for a store at Ganganagar Bus Stop. The suspension, effective from December 10, 2025, was issued under the Drugs and Cosmetics Act and Rules, with the company estimating a potential revenue loss of ₹2.40 lacs during this period.

11Dec 25

MedPlus Health Services Subsidiary Receives Favorable High Court Order in Tax Dispute Case

MedPlus Health Services announced that its subsidiary Optival Health Solutions received a favorable order from the High Court of Telangana on November 21, 2025, in a tax dispute case involving ₹43.45 crores for Assessment Year 2020-21. The court disposed of the writ petition favorably, and the company confirmed no financial impact on operations.

11Dec 25

MedPlus Health Services Unit Receives Favorable Court Ruling in Telangana

MedPlus Health Services announced that its company unit received a positive court ruling in Telangana. The healthcare retail company has not provided specific details about the legal proceedings or the court's decision. This represents a favorable legal outcome for the pharmacy chain's operations in the state.

10Dec 25

MedPlus Health Services Subsidiary Receives Drug License Suspension Order in Karnataka

MedPlus Health Services Limited disclosed that its subsidiary Optival Health Solutions Private Limited received a one-day drug license suspension order for its store in Hubli, Karnataka. The order was issued by the Assistant Director, Drugs Control Administration under the Drugs and Cosmetics Act, with a potential revenue loss of ₹0.58 lacs.

20Nov 25

MedPlus Subsidiary Faces Drug License Suspension in Karnataka

Optival Health Solutions, a subsidiary of Medplus Health Services, received suspension orders for drug licenses at two stores in Karnataka. The suspensions, issued by the Assistant Director of Drugs Control Administration in Hubli, will last for 3 days each at stores on R N Shetty Road and Vidyanagar Shirur Park. The potential revenue loss is estimated at Rs 3.49 lacs. The orders were issued under the Drugs and Cosmetics Act, 1940, and related Rules, 1945.

18Nov 25

MedPlus Subsidiary Faces Three-Day Drug License Suspension in Karnataka

Optival Health Solutions, a subsidiary of MedPlus Health Services, received a three-day suspension order for its drug license at a store in Hubli, Karnataka. The suspension, issued under the Drugs and Cosmetics Act, 1940 and Rules, 1945, was received on November 17, 2025. The estimated financial impact is a potential revenue loss of approximately Rs. 1.08 lacs. MedPlus promptly informed stock exchanges of this development in compliance with SEBI regulations.

09Nov 25

MedPlus Subsidiary Faces Drug License Suspensions in Telangana and Andhra Pradesh

Medplus Health Services Limited announced that its subsidiary, Optival Health Solutions Private Limited, received suspension orders for drug licenses at two stores in Telangana and Andhra Pradesh. Each store faces a two-day suspension under the Drugs and Cosmetics Act. The company estimates a combined revenue loss of Rs 1.73 lacs due to these suspensions. Medplus has committed to providing detailed information on its website and stock exchange platforms.

03Nov 25

Medplus Health Services Reports 43% Jump in Quarterly Net Profit

Medplus Health Services announced strong financial results for the latest quarter. Net profit increased by 43.4% to ₹555.00 million, while revenue grew 6.5% to ₹16.79 billion. EBITDA rose 21% to ₹1.50 billion, with the EBITDA margin expanding to 8.86%. The company's subsidiary, Optival Health Solutions, received a 21-day suspension order for a drug license at a Nagpur store, potentially resulting in a ₹4.34 lakh revenue loss.

02Nov 25

MedPlus Subsidiary Faces Multiple Drug License Suspensions in Maharashtra and Andhra Pradesh

Optival Health Solutions, a subsidiary of Medplus Health Services, has received multiple drug license suspension orders for its stores in Maharashtra and Andhra Pradesh. The latest suspension in Maharashtra is for 25 days, potentially causing a revenue loss of Rs 5.87 lacs. Previous suspensions include a 21-day order in Nagpur and a 7-day order in Rajamahendravaram, with estimated revenue losses of Rs 4.34 lacs and Rs 1.75 lacs respectively. These regulatory actions highlight compliance challenges for pharmaceutical retail chains in India.

01Nov 25

MedPlus Health Services Receives Stay Orders Against Suspension in Maharashtra, Faces Drug License Suspension in Andhra Pradesh

MedPlus Health Services Limited has received stay orders against suspensions in Nagpur and Amravati, Maharashtra. In Andhra Pradesh, its subsidiary Optival Health Solutions Private Limited faces a seven-day drug license suspension for a store in Rajamahendravaram, potentially causing a revenue loss of Rs 1.75 lakhs. The company operates 4,930 stores across 13 states and one union territory, serving over 750 cities in India.

31Oct 25

MedPlus Health Services Unveils Ambitious Expansion Strategy with 120-150 New Stores Quarterly

MedPlus Health Services, India's second-largest pharmacy retailer, announces plans to add 120-150 new stores quarterly. The expansion focuses on Tier-2 cities and beyond, using a cluster-based approach. The company aims to increase its private-label product mix and enhance omni-channel capabilities with 2-hour delivery services. MedPlus currently operates 4,930 stores across 13 states and 1 union territory, with recent financial results showing revenue growth of 6.50% YoY to ₹16,793.00 million and improved gross margins.

31Oct 25

MedPlus Health Services Reports 43% Surge in Q2 Net Profit, Revenue Up 6.5%

Medplus Health Services announced strong Q2 results with a 43% year-over-year increase in consolidated net profit to ₹555.00 million. Revenue grew by 6.5% to ₹16.79 billion. EBITDA rose to ₹1.50 billion, with the EBITDA margin expanding to 8.86%. The company's management attributed the performance to strategic initiatives enhancing efficiency and market presence.

25Oct 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Stores

Optival Health Solutions, a subsidiary of MedPlus Health Services, has received suspension orders for drug licenses at two store locations in Karnataka and Telangana. The suspensions, lasting 5 and 3 days respectively, were issued under the Drugs and Cosmetics Act. The company estimates a potential revenue loss of Rs 1.51 lacs due to these suspensions. MedPlus has disclosed this information in compliance with SEBI regulations.

22Oct 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Karnataka Stores

Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at two store locations in Karnataka. The Vijayapura store faces a 5-day suspension with an estimated revenue loss of Rs. 1.12 lakhs, while the Rajarajeshwari Nagar store has a 1-day suspension with an expected loss of Rs. 1.71 lakhs. The suspensions were issued under the Drugs and Cosmetics Act, 1940 and Rules, 1945.

22Oct 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores

Optival Health Solutions, a subsidiary of Medplus Health Services Limited, received suspension orders for drug licenses at two stores in Telangana. The Assistant Director of Drugs Control Administration, Medchal, issued the orders due to violations under Rule 65 of the Drugs and Cosmetics Act, 1940 and Rules, 1945. The Balanagar Ground Floor store faces a 2-day suspension with an estimated revenue loss of Rs. 0.48 lacs, while the 3rd Phase Kphb store has a 5-day suspension with an estimated loss of Rs. 1.28 lacs. Total estimated revenue loss is Rs. 1.76 lacs.

19Oct 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores

Optival Health Solutions, a subsidiary of MedPlus Health Services Limited, has received suspension orders for drug licenses at two stores in Telangana due to violations under the Drugs and Cosmetics Act. The Balanagar Ground Floor store faces a 2-day suspension with an estimated revenue loss of Rs. 0.48 lacs, while the 3rd Phase KPHB store faces a 5-day suspension with an estimated revenue loss of Rs. 1.28 lacs. The suspensions were issued on October 18, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945. MedPlus has disclosed this information in compliance with SEBI regulations.

15Oct 25

MedPlus Subsidiary Faces 3-Day Drug License Suspension in Telangana

Optival Health Solutions, a subsidiary of Medplus Health Services, received a three-day suspension order for its drug license at a store in Kapra Saket, Telangana. The suspension, issued by the Assistant Director of Drugs Control Administration, Quthubullapur, is expected to result in a revenue loss of approximately Rs. 0.22 lacs. Medplus Health Services disclosed this information in compliance with SEBI regulations.

14Oct 25

MedPlus Subsidiary Faces 7-Day Drug License Suspension in Andhra Pradesh

Medplus Health Services' subsidiary, Optival Health Solutions, received a seven-day suspension order for a drug license at its store in Devi Chowk, Andhra Pradesh. The order, issued on October 13, 2025, cites Rule 65 of the Drugs and Cosmetics Act. The estimated revenue loss from this suspension is Rs. 1.75 lakhs. Medplus has disclosed this information in compliance with SEBI regulations and will provide detailed information on its website and stock exchange platforms.

25Sept 25

MedPlus Subsidiary Faces 15-Day Drug License Suspension in Maharashtra

Optival Health Solutions, a subsidiary of Medplus Health Services, received a 15-day suspension order for a drug license at its Nagpur store. The suspension, issued by the Assistant Commissioner & Licensing Authority of Food & Drug Administration, Nagpur, cites a violation under the Drugs and Cosmetics Act. Medplus estimates a potential revenue loss of approximately Rs. 2.29 lakhs due to this suspension.

22Sept 25

MedPlus Subsidiary Faces 7-Day Drug License Suspension in Andhra Pradesh

Optival Health Solutions, a subsidiary of Medplus Health Services, received a seven-day suspension order for a Drug License at one of its stores in Andhra Pradesh. The suspension, issued by the local Drug Control Administration, cites violations under the Drugs and Cosmetics Act. Medplus estimates a potential revenue loss of Rs. 1.48 lakhs due to the week-long closure. The company disclosed this information in compliance with SEBI regulations.

19Sept 25

MedPlus Subsidiary Faces Drug License Suspensions at Multiple Stores, Revenue Impact Rises

Medplus Health Services' subsidiary, Optival Health Solutions, has received drug license suspensions in four states: Karnataka (3 days), Andhra Pradesh (10 days), Chhattisgarh (5 days), and Telangana (4 days). The suspensions, issued under the Drugs and Cosmetics Act, affect store locations in each state. The total potential revenue impact is estimated at Rs 9.45 lakhs. Medplus disclosed this information in compliance with SEBI regulations.

18Sept 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Stores, Expects Rs 4.06 Lacs Revenue Loss

Optival Health Solutions, a subsidiary of Medplus Health Services, received suspension orders for drug licenses at two store locations in Bilaspur and Mahabubnagar. The suspensions, lasting five and four days respectively, are expected to result in a potential revenue loss of Rs 4.06 lacs. The company disclosed this information in compliance with SEBI regulations.

09Sept 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores

Optival Health Solutions, a subsidiary of Medplus Health Services Limited, received suspension orders for drug licenses at two stores in Telangana. The West Marredpally Circle store faces a one-day suspension, while the Vijayapuri Colony South Lalaguda Road store faces a four-day suspension. The estimated revenue loss is Rs. 0.57 lakhs and Rs. 0.93 lakhs respectively. The suspensions were issued under the Drugs and Cosmetics Act, 1940 and Rules, 1945.

04Sept 25

MedPlus Subsidiary Faces Two-Day Drug License Suspension in Telangana

Optival Health Solutions, a subsidiary of Medplus Health Services, received a two-day suspension order for a drug license at its store in Boduppal Brundavan Colony, Telangana. The suspension, issued by the Assistant Director of Drugs Control Administration, Shameerpet, was due to violations under the Drugs and Cosmetics Act and Rules. The company estimates a potential revenue loss of Rs. 0.81 lacs for the affected store. Medplus has disclosed this information in compliance with SEBI regulations.

26Aug 25

MedPlus Subsidiary Faces Drug License Suspensions in Karnataka

Medplus Health Services Limited's subsidiary, Optival Health Solutions, received drug license suspension orders for two stores in Karnataka. One store in Kotturu faces a two-day suspension with an estimated revenue loss of Rs. 0.28 lakhs, while another in Hoskote faces a one-day suspension with a potential loss of Rs. 0.78 lakhs. The total estimated revenue loss is approximately Rs. 1.06 lakhs. The suspensions were issued under the Drugs and Cosmetics Act, 1940 and the Drugs and Cosmetics Rules, 1945.

23Aug 25

MedPlus Subsidiary Faces 30-Day Drug License Suspension in Maharashtra

Medplus Health Services' subsidiary, Optival Health Solutions, has received a 30-day suspension order for its drug license at a store in Amravati, Maharashtra. The suspension, issued by the Assistant Commissioner & Licensing Authority of Food & Drug Administration, is expected to result in a potential revenue loss of approximately Rs. 6.45 lakhs. The company has disclosed this information in compliance with SEBI regulations.

19Aug 25

MedPlus Subsidiary Faces Drug License Suspensions at Three Stores, Potential Revenue Loss of Rs 6.89 Lacs

Medplus Health Services' subsidiary, Optival Health Solutions, has received suspension orders for drug licenses at three stores in Karnataka and Maharashtra. The suspensions, lasting 2-7 days, are expected to result in a potential revenue loss of approximately Rs 6.89 lacs. The orders were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.

15Aug 25

MedPlus Subsidiary Faces Four-Day Drug License Suspension in Telangana

Medplus Health Services Limited's subsidiary, Optival Health Solutions, received a four-day suspension order for its drug license at a store in Quthubullapur, Telangana. The suspension, citing violations under the Drugs and Cosmetics Act, is expected to result in a potential revenue loss of approximately Rs. 0.80 lakhs. The company promptly reported this development to stock exchanges in compliance with SEBI regulations.

07Aug 25

MedPlus Health Services Reports Q1 Results: Revenue Growth Amid Expansion and Private Label Push

MedPlus Health Services reported Q1 consolidated revenue of Rs. 15,426.00 million with an operating EBITDA of Rs. 728.00 million. Pharmacy operations grew 6.6% year-on-year on GMB basis. The company added 124 new stores, reaching a total of 4,813 stores. Private label sales constituted 21.5% of total revenue. The diagnostic segment showed strong growth with revenue increasing to Rs. 302.90 million. CEO acknowledged supply chain challenges but expressed optimism for improvement. Subsidiary Optival Health Solutions received suspension orders for drug licenses at eight stores across three states, with minimal expected financial impact.

06Aug 25

MedPlus Subsidiary Faces Drug License Suspensions Across Three States

Optival Health Solutions, a subsidiary of Medplus Health Services, received eight drug license suspension orders affecting stores in Karnataka, Telangana, and Maharashtra. The suspensions range from 1 to 15 days, impacting 8 stores across the three states. The potential total revenue loss is estimated at 20.21 lacs. The most severe suspension is a 15-day order for a store in Nagpur, Maharashtra, with a potential revenue loss of 12.00 lacs. The suspensions were issued by various state drug control authorities for violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945.

02Aug 25

MedPlus Health Services Reports 195% Surge in Q1 Profit, Approves Key Appointments

MedPlus Health Services Limited reported a 195% increase in net profit to Rs 423.43 million for Q1 FY2024. Revenue from operations grew to Rs 15,426.34 million. The retail segment remained the primary revenue driver. The company approved key appointments including Cost Auditor and Secretarial Auditor, and allotted 79,157 equity shares under the Employee Stock Option Plan 2021. A subsidiary received a two-day suspension order for a drug license in Karnataka.

02Aug 25

MedPlus Subsidiary Faces Two-Day Drug License Suspension in Karnataka

Medplus Health Services' subsidiary, Optival Health Solutions, received a two-day drug license suspension for a store in Karnataka. The suspension, issued by the Assistant Director of Drugs Control Administration, Bangalore Circle – Bidar, is expected to result in a revenue loss of approximately Rs. 0.18 lakhs for the affected store. Medplus has disclosed this information in compliance with SEBI regulations.

31Jul 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores

Optival Health Solutions, a subsidiary of MedPlus Health Services Limited, has received suspension orders for drug licenses at two stores in Telangana. The suspensions, issued by the Assistant Director of Drugs Control Administration in Warangal, affect a store in Station Ghanpur for five days and another in Jangaon, Warangal for three days. The estimated revenue loss is 0.98 lakhs for the Station Ghanpur store and 0.40 lakhs for the Jangaon store. MedPlus has notified the BSE and NSE about this development in compliance with SEBI regulations.

31Jul 25

MedPlus Subsidiary Faces Drug License Suspensions at Two Telangana Stores

Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at two stores in Telangana. The Station Ghanpur store faces a five-day suspension, while the Jangaon store faces a three-day suspension. The estimated revenue loss is Rs. 0.98 lacs and Rs. 0.40 lacs respectively. The suspensions were issued for violations under the Drugs and Cosmetics Act and Rules. MedPlus promptly disclosed this information in compliance with SEBI regulations.

29Jul 25

MedPlus Subsidiary Faces One-Day Drug License Suspension in Karnataka

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a one-day suspension order for its drug license at a store in Gadag, Karnataka. The order was issued by the Assistant Director of Drugs Control Administration under the Drugs and Cosmetics Act. The company estimates a potential revenue loss of Rs. 0.21 lacs due to this suspension. Medplus Health Services has disclosed this information to stock exchanges in compliance with SEBI regulations.

26Jul 25

MedPlus Subsidiary Faces 3-Day Drug License Suspension in Visakhapatnam

Optival Health Solutions, a subsidiary of Medplus Health Services, received a three-day drug license suspension order for a store in Visakhapatnam, Andhra Pradesh. The suspension, citing violations under the Drugs and Cosmetics Act, is expected to result in a potential revenue loss of Rs. 0.69 lakhs. The company disclosed this information in compliance with SEBI regulations.

23Jul 25

MedPlus Subsidiary Faces 3-Day Drug License Suspension in Tamil Nadu

Optival Health Solutions, a subsidiary of Medplus Health Services, received a three-day suspension order for a drug license at its store in MGR Nagar, Tamil Nadu. The suspension, issued on July 22, 2025, cites violations under the Drugs and Cosmetics Act, 1940 and Rules, 1945. The company estimates a potential revenue loss of Rs. 3.03 lakhs due to this temporary suspension. Medplus Health Services disclosed this incident in compliance with SEBI regulations.

15Jul 25

MedPlus Health Services Subsidiary Faces Drug License Suspensions in Karnataka and Telangana

Optival Health Solutions, a subsidiary of MedPlus Health Services, received suspension orders for drug licenses at five retail pharmacy outlets in Karnataka and Telangana. The suspensions, lasting 2 to 7 days, were issued between July 10-14, 2025, under the Drugs and Cosmetics Act. The company estimates potential revenue losses of approximately ₹4.78 lakh across the affected stores. The suspensions were issued under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. MedPlus has disclosed this information in compliance with SEBI regulations.

27May 25

MedPlus Health Services Reports 53.6% Surge in Q4 Net Profit

MedPlus Health Services announced impressive Q4 results with net profit soaring 53.6% year-over-year to ₹51.30 crore, despite a modest 1.3% revenue increase to ₹1,510.00 crore. The company demonstrated significant improvements in operational efficiency, with EBITDA rising 42.7% to ₹145.00 crore and operating profit margin expanding to 8.49% from 6.37% in the previous year. These results highlight MedPlus's effective cost management and operational strategies in the competitive Indian pharmacy retail sector.